Robinhood Is Opening the Door to U.S. Cannabis With Reform On the Horizon
Trulieve, Curaleaf, and Green Thumb Industries showed up on the app this week as the federal government inches toward reclassifying recreational marijuana.
Cannabis, Wellness And Beverages: Three Names To Watch
Tilray, Canopy Growth and Cronos are three US-listed names at the intersection of cannabis, wellness and beverages.
Cannabis Stocks On NASDAQ Markets: A Guide For U.S.
Discover how U.S.-traded cannabis stocks work, what defines the cannabis universe on NASDAQ and OTC markets, and what U.S. investors typically consider.
Cannabis MSO Curaleaf prepares for uplisting on US stock exchanges
Curaleaf will execute a 1-for-3 reverse stock split positioning it to uplist to a U.S. stock exchange cannabis rescheduling creates an opening to do so.
Should you buy CGC stock after marijuana reclassification?
Canopy Growth Corporation CGC is back in focus as marijuana reclassification efforts revive investor interest in cannabis stocks. While the regulatory shift has improved sentiment across the sector, …
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Should you buy CGC stock after marijuana reclassification?
Canopy Growth Corporation CGC is back in focus as marijuana reclassification efforts revive investor interest in cannabis stocks. While the regulatory shift has improved sentiment across the sector, …
‘Devastating’: Retired firefighter says he lost most of his retirement savings investing in stocks that were targeted by a famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Retired firefighter says he lost most of his savings investing in stocks that were targeted by famous short-seller
He turned $110K into $190K, then watched his savings vanish after public criticism from from Citron Research’s Andrew Left.
Canopy Growth’s Stock Just Dropped — Here’s Why I’m Still Not Buying
For anyone who has observed Canopy Growth (NASDAQ: CGC) during the past few years, it won’t be shocking to learn that the marijuana company’s stock is diving in May. Since the start of the month, it’s …
Buy this cannabis stock for a double, analyst says
Haywood analyst Neal Gilmer maintained a “Buy” rating and $3.25 target on Organigram Holdings (Organigram Global Stock Quote, Chart, News, Analysts, Financials TSX:OGI) in a M …
Is Canopy Growth Stock Finally Setting Up for a Real Turnaround?
Canopy Growth (NASDAQ: CGC) has made considerable efforts to turn itself around. Over the past few years, the Canada-based cannabis company has significantly reduced its outstandi …
Canopy Growth Is One of the Market’s Most Polarizing Stocks: 3 Scenarios for the Next 12 Months
After years of heavy losses and repeated restructurings, Canopy Growth is showing early signs of stabilization.
Cannabis Revenue Decline Pressures Organigram Earnings Despite Germany Expansion (OGI)
Organigram reported weaker second-quarter revenue and profitability as vape and infused pre-roll sales slowed, while the company positioned its Sanity Group acquisition as a major international growth …
This weed stock is undervalued, analyst says
The analyst expects Trulieve to generate Adjusted EBITDA of US$401.1-million on revenue of US$1.178-billion in fiscal 2026, improving to US$415.8-million on revenue of US$1.221-billion in fiscal 2027.
Recent Comments